

ATTORNEY DOCKET NO. I

Examiner: Not Yet Assigned

Art Unit: Not Yet Assigned

SUPPLEMENTAL INFORMATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFIC

In re application of: Jean-Michael Scherrman et al Serial No.: 10/045,971

For: Cocaethylene immunogens and antibodies

DISCLOSURE STATEMENT

BOX DD

Filed: January 9, 2002

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

This Supplemental Information Disclosure Statement is hereby submitted in accordance with 37 CFR 1.98(a)(2)(iii) requiring submission of copies of cited pending U.S. patent applications, and pursuant to Applicant's continuing duty under 37 CFR 1.56 to bring any information which may be material to patentability of this application to the Examiner's attention.

Please find a copies of references A1-A3 previously listed on the PTO-1449 submitted on January 9, 2002. Copies of all references have been submitted

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an

Printed Name: Courancy Mayor

ATTORNEY DOCKET NO. DASI.002.03US

that the information submitted herewith is in fact material.

The subject application is believed patentable over any of the above references.

Respectfully submitted,

Dated: march + LOOZ

Barbara Rae-Venter, Ph.D.

Reg. No. 32,750

Rae-Venter Law Group, P.C. PO Box 1898

Monterey, CA 93942-1898

Phone: (831) 648-3090 Facsimile: (831) 242-0137

BRV/cs



COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

Sheet 1 of 2

]

In re the application of: Jean-Michael Scherrman, et al.]

Art Unit: Not Yet Assigned

Serial No. Not Yet Assigned

Examiner: Not Yet Assigned

Filed: January 9, 2002

	U.S. PATENT DOCUMENTS							
Ref. Desig.	Examiner's <u>Initials</u>	Document Number	<u>Date</u>	<u>Name</u>	Class/ Subclass	Filing Date		
Al		3,917,582	11/4/75	Soffer et al	260/121	6/13/73		
A2		4,045,420	8/30/77	Soffer et al	260/121.R	5/29/73		
A3		3,888,866	6/10/75	Leute et al	260/292	6/1/73		
A4		5,817,770	10/6/98	Scherrmann et al	530/389.8			
A5		5,202,270	4/13/93	Ungemach et al	436/537			
A6		5,760,184	6/2/1998	Swain et al	530/387.1	11/28/199		

PENDING U.S. PATENT DOCUMENTS					
Ref.	Examiner's				
Desig.	Initials	Document Number		<u>Name</u>	Filing Date
Bl		WO 96/30049	10/3/96		WIPO
B2		WO 91/19980	12/26/91		WIPO
B3		0467783	1/22/92		EP
B4		0475783	3/18/92		EP
B5		WO 93/12111	6/24/93		WIPO

Examiner:	Date Considered:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.





COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

Sheet <u>2</u> of <u>2</u>

In re the application of: Jean-Michael Scherrman, et al.]

Art Unit: Not Yet Assigned

Serial No. Not Yet Assigned

Examiner: Not Yet Assigned

Filed: January 9, 2002

FOREIGN PATENT DOCUMENTS

Date

Ref. Desig. Examiner's

Initials

Document Number

Country

Class/ Subclass

Date Considered:

Filing Date

NONE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref.

Examiner's

Desig.

Initials

C1

Oyler et al (Oct 1996) Analytical Toxicology 20:6:453-62.



ATTORNEY DOCKET NO. DASI.00 138 US

R167	OUT THE STATE OF T	IN THE UNITED STATES PATENT	ΑN	ND TRADEMARK OFFICE	CENTER 1600/2900	
AFAL.	applica	tion of: Jean-Michael Scherrman et al)	Examiner:	600/29	
Seria	ıl No.:	10/045,971)	Art Unit:	8	
Filed: January 9, 2002)	SUPPLEMENTAL INFORMA	<u> TION</u>	
For: Cocaethylene immunogens and antibodies)	DISCLOSURE STATEMENT TRANSMITTAL		
	stant Co nington,	mmissioner for Patents D.C. 20231 smitted herewith is:				
	[X]	A Supplemental Information Disclosure Statement.				
	[X]	A copy of PTO-1449 previously submitted on January 9, 2002.				
	[X]	Copies of references A1-A3 as listed on the PTO-1449 submitted on January 9, 2002.				
	[]	An International Search Report.				
	[X]	Return postcard (postage prepaid).				

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the U.S. Patent and Trademark Office, PO Box 2327, Arlington, VA 22202 on 12002

Printed Name: Courney Mayer

ATTORNEY DOCKET NO. DASI.002.03US

1.	[X]	This Information Disclosure Statement is filed <u>before</u> the later of:				
		[X]	three months from the filing date of a national application other than a continued prosecution application under §1.53(d);			
		[]	three months from the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application;			
		[]	the mailing of a first office action on the merits; or			
		[]	the mailing of a first Office Action after the filing of request for continued examination under §1.114.			
	[X]	In acc	cordance with 37 C.F.R. § 1.97(b), no fee is required.			
2.	[]		Information Disclosure Statement is filed after the events noted in paragraph before either:			
		[]	a final action under 37 C.F.R. § 1.113;			
		[]	a Notice of Allowance under 37 C.F.R. § 1.311; or			
		[]	an action that otherwise closes prosecution in the application.			
	[]	In acc	cordance with 37 C.F.R. § 1.97(c) also enclosed is:			
		[]	a fee under 37 C.F.R. § 1.17(p) in the amount of \$180.00; or			
		[]	a certification as stated below.			
3.	[]		information Disclosure statement is filed on or before the payment of the fee, but after either:			
		[]	a final action under 37 C.F.R. § 1.113;			
		[]	a Notice of Allowance under 37 C.F.R. § 1.311; or			
		[]	an action that otherwise closes prosecution in the application.			

PATEN	i T []	ATTORNEY DOCKET NO. DASI.002.03US In accordance with 37 C.F.R. § 1.97(d) also enclosed is:					
		[]	a certification, as stated below; and				
		[]	a fee under 37 C.F.R §1.17(p) in the amount of \$180.00.				
<u>Certifi</u>	<u>cation</u>						
	The ur	ndersig	igned also states:				
	h item of information contained in the Information Disclosure Statemein was first cited in a communication from a foreign Patent Office in interpart foreign application not more than three months prior to the fais Information Disclosure Statement; or	a					
	[]	subm coun made § 1.5	item of information contained in the Information Disclosure Statement mitted herewith was cited in a communication from a foreign patent of interpart foreign application or, to the knowledge of the undersigned, le reasonable inquiry, was known to any individual designated in 37 (56(c) more than three months prior to the filing date of this Informaticlosure Statement.	office in a having C.F.R.			
		The f	fees indicated above are:	\$			
			TOTAL	FEES: \$			
[]	A chec	ck incl	cluding the amount of the above-indicated TOTAL FEES is attached.				
[]	Please	ase charge Deposit Account No. 18-0020 in the amount of: \$					
[]	A chec	neck in the amount of \$ is attached.					
[X]	No fee	ee is required.					
[X]	The Commissioner is hereby authorized to charge any underpayment of the following fees associated with this communication, including any necessary fees for extension of time, or credit any overpayment to Deposit Account No. 18-0020.						
	[X] A	ny fili	ing fees under 37 C.F.R. § 1.16 for the presentation of extra claims.				
	[X] A	.ny pat	atent application processing fees under 37 C.F.R. § 1.17.				

ATTORNEY DOCKET NO. DASI.002.03US

[X] A duplicate copy of this sheet is attached for accounting purposes.

Respectfully submitted,

Dated: Mawy 1002

Barbara Rae-Venter, Ph.D.

Reg. No. 32,750

Rae-Venter Law Group, P.C. PO Box 1898 Monterey, CA 93942-1898 Phone: (831) 648-3090

Facsimile: (831) 242-0137

BRV/cs